Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152509 | 0.89 | NPC1 (0.34) | MAPTRAB9ANPC1 | |
| SCHEMBL6153096 | 0.84 | TRPV1 (0.39) | LMNAMAPTRAB9ASMN1; SMN2HTT | |
| SCHEMBL6152503 | 0.81 | TRPA1 (0.34) | MAPTALDH1A1KMT2A | |
| SCHEMBL6152448 | 0.76 | ALDH1A1 (0.44) | PDE2ALMNARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6152423 | 0.74 | PDE2A (0.33) | PDE2AMAPT | |
| SCHEMBL6152451 | 0.72 | PPIA (0.40) | — | |
| SCHEMBL6152273 | 0.70 | PDE2A (0.36) | PDE2ALMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6152041 | 0.70 | GAA (0.40) | LMNAMAPTRAB9ASMN1; SMN2HTT | |
| SCHEMBL6152524 | 0.67 | CRHBP (0.41) | LMNAMAPTRAB9ASMN1; SMN2HTT | |
| SCHEMBL26350587 | 0.67 | BRD4 (0.53) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943181-B2 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2005-09-13 | — | — | US | claimed |
| EP-1406610-B1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-01-26 | — | — | EP | claimed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | claimed |
| EP-1406610-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004016-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| US-6943181-B2 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2005-09-13 | — | — | US | disclosed |
| EP-1406610-B1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1406610-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004016-A1 | USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | BACE1, MYC, APP | PDE2A 3142/4885LMNA 811/4885MAPT 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.